Name of journal: *World Journal of Hepatology*

ESPS Manuscript NO: 16100

Columns: REVIEW

**Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues**

Rapti I *et al.* HBV treatment and HCC

Irene Rapti, Stephanos Hadziyannis

**Irene Rapti,** Athens Medical Center, National and Kapodistrian University of Athens, Evgenidion Hospital of Athens, 15669 Athens, Greece

**Irene Rapti, Stephanos Hadziyannis,** Liver Unit and its Molecular Biology Laboratory, National and Kapodistrian University of Athens, Evgenidion Hospital of Athens, 15669 Athens, Greece

**Author contributions:** Both authors contributed to this manuscript.

**Conflict-of-interest:** None.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Stephanos Hadziyannis, Emeritus Professor** of Medicine and Hepatology, Liver Unit and its Molecular Biology Laboratory, National and Kapodistrian University of Athens, Evgenidion Hospital of Athens, 4 Dirrachiou Str., 15669 Athens, Greece. hadziyannis@ath.forthnet.gr

**Telephone:** +30-21-06516807

**Fax:** +30-21-06543299

**Received:** December 26, 2014

**Peer-review started:** December 30, 2014

**First decision:** January 20, 2015

**Revised:** March 3, 2015

**Accepted:** March 16, 2015

**Article in press:**

**Published online:**

**Abstract**

Hepatocellular carcinoma (HCC) is a major health problem worldwide, representing one of the leading causes of death. Chronic hepatitis B (CHB) is the most important etiologic factor of this tumor, accounting for the development of more than 50% of the cases in the world. Primary prevention of HCC is possible by hepatitis B vaccination conferring protection from hepatitis B virus (HBV) infection. However, according to the WHO Hepatitis B Fact sheet No 204 (update of July 2014) globally there exists a large pool of > 240 million people chronically infected with HBV who are at risk for development of HCC. These individuals represent a target population for secondary prevention both of cirrhosis and of HCC. Since ongoing HBV replication in chronic HBV infection (CHB) is linked with the progression of the underlying liver disease to cirrhosis as well as with the development of HCC, effective antiviral treatment in CHB has also been evaluated in terms of secondary prevention of HCC. Currently, most patients with active CHB are subjected to long term treatment with the first line nucleos(t)ide analogues Entecavir and Tenofovir. These compounds are of high antiviral potency and have a high barrier to HBV resistance compared to lamivudine, adefovir dipivoxil and even telbivudine. Many studies have shown that patients under antiviral treatment, especially those in virological remission, develop less frequently HCC compared to the untreated ones. However, the risk for development of HCC cannot be eliminated. Therefore, surveillance for the development of HCC of patients with chronic hepatitis B must be lifelong or until a time in the future when new treatments will be able to completely eradicate HBV from the liver particularly in the early stages of CHB infection. In this context, the aim of this review is to outline the magnitude of the risk for development of HCC among patients with CHB, in the various phases of the infection and in relation to virus, host and environmental factors as evaluated in the world literature. Moreover, the benefits of antiviral treatment of CHB with nucleos/tide analogs, which have changed the natural history of the disease and have reduced but not eliminated the risk of HCC are also reviewed.

**Key words:** Hepatitis B virus; Chronic hepatitis B; Cirrhosis; Hepatocellular carcinoma; Treatment; Interferon; Nucleos(t)ide analogues; Lamivudine; Adefovir; Entecavir; Tenofovir; Virological remission

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Hepatocellular carcinoma (HCC) represents a major health problem worldwide. It develops on the grounds of chronic liver disease, with chronic hepatitis B (CHB) being responsible for more than 50% of HCC worldwide. Currently, the vast majority of patients with CHB are being treated with nucleos(t)ide analogues, which have changed the natural history of the disease, reducing at a considerable extent its long-term consequences. However, although the risk of HCC has also been reduced, it has not been eliminated even after HBsAg loss or seroconversion. Therefore, constant surveillance, according to guidelines should never be omitted, unless new more potent treatment options are identified.

Rapti I, Hadziyannis S. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. *World J Hepatol* 2015; In press

**INTRODUCTION**

Hepatocellular carcinoma (HCC) represents a major health problem, being one of the leading causes of death worldwide with 782000 new cases diagnosed in 2008 and highest incidence rates being reported in East/Southeast Asia, North and West Africa[1]. It is the 5th most common tumor in men accounting for 7.5% of the total number of tumors and the 9th most common in women (3.4% of the total number of tumors in them), while it stands as the 2nd commonest cause of death due to cancer in the world (746000 deaths in 2012)[2]. It has a very bad prognosis with a 14% 5-year survival from diagnosis, being worse than lung, esophagus or stomach cancer and better only in comparison to the 5-year survival of 6% of pancreatic cancer[3].

HCC usually develops on the grounds of chronic liver disease, particularly cirrhosis mainly due to the hepatitis B virus (HBV) or C virus (HCV), with HBV being responsible for more than 50% of the world cases of HCC, reaching 78% in areas of high HCC incidence[4,5]. Patients with chronic hepatitis B (CHB) are at a 100-fold higher risk for developing HCC compared to healthy individuals while HBV cirrhotic patients are at an even higher risk[5,6].

From an historical point of view it is noteworthy that the link of HCC with chronic HBV infection was first pointed out in 1969 and 1970 in Europe, a geographical area in which HCC was previously thought to be extremely rare to practically non-existent. Up to those days the etiology of HCC was linked with exposure to aflatoxinwhich was particularly common in Sub-Saharan Africa, an area of high HCC incidence. Thus, it came out of a surprise when in 1970 2 clinical reports one from England and one from Greece published in Lancet pointed out that Australia antigen, a marker of HBV infection, already referred in those days as hepatitis associated antigen (HAA), prevailed in patients with cryptogenic chronic liver disease and cirrhosis and that a significant percentage of such patients developed HCC[7,8]. As stressed by Sherlock[9] in 1971 up to those early days the link between HBV infection and HCC had been missed by B.S.Blumberg the scientist who had discovered HBsAg. This is obvious by the content of a letter he published in 1969 in Lancet[10] despite his subsequent claims[11]. However, regardless of the early European data on the possible link between chronic hepatitis B in the development of HCC, it was only in the mid 1970s that the etiological role of chronic HBV infection in HCC was unequivocally established thanks to the large prospective studies of Beasley *et al*[6] in Taiwan. On the other hand, the early observations in Greece on the possible link between chronic HBV infection and HCC have stimulated further clinical research in the country aiming at the identification of risk factors, determinants and predictors of development of HCC[8,12-15]. They have also been followed by epidemiological studies with positive results disclosing an association between the prevalence of HBsAg in the various geographical departments of the Country and the incidence of HCC in the same areas.

To sum up, HCC is a major health problem especially in patients with chronic liver disease and mainly CHB with or without cirrhosis, established since the early 70s and therefore, the possible elimination of this risk with oral treatment is considerably important.

**RISK FACTORS**

The risk for development of HCC in CHB differs significantly between the various areas of the world being highest in Asian and African patients[16-20]. It is also higher in males than in females with CHB[21-23], in patients older than 40 years and in cirrhotics compared to non-cirrhotic ones[18,22,24]. Its incidence increases if the patient has a family history of HCC[25], if the viral load (HBV-DNA) is high[21,26,27], if the genotype of the infecting HBV is C[28,29] and if pre-core or basic core promoter mutations have developed[30,31]. The risk also increases in patients with heavy alcohol consumption[32,33], in those co-infected with HDV or/and HCV[34-37] and in those who consume unsafely stored crops (dietary exposure to aflatoxin)[38]. In the evaluation of the risk for HCC by variables of activity of HBV replication, a linear association with serum HBV-DNA levels has been proved, while, more recently, high levels of HBsAg (> 1000 IU/mL), even in patients with relatively low viral loads (2000-20000 IU/mL) have been reported to confer medium to high risk for HCC development[21,39,40]. As far as baseline viral load is concerned, in a large prospective cohort study of 3653 patients, the cumulative incidence rate of HCC at the end of follow-up ranged from 1.3%, when baseline serum HBV-DNA was less than 300 copies/mL, to 14.89% for a viral load of ≥ 6 log10 copies/mL[21].

**PATHOGENETIC MECHANISMS IN HCC**

Several molecular mechanisms have been implicated in the pathogenesis of HBV-linked HCC. In the 1980s the identification of integration of HBV-DNA into the genome of hepatocytes in patients with HCC, has been implicated in the development of HBV-related HCC with several HCC cases being reported harboring integrated HBV DNA sequences in the malignant hepatocytes while serum and non-malignant liver tissue was negative for any marker of active HBV infection[15]. The protein HBx and the epigenetic regulation of of the minichromosome of covalently closed circular HBV DNA (cccDNA) have also been implicated as factors contributing to chromosomal instability, to activation of cancer-related genes and to inactivation of protective genes. They have also been considered to interfere with cellular transcription and signal transduction through various pathways and cellular promoters[41-43]. Moreover, adaptive immune reactions developing as a consequence of chronic HBV infection result in release of cytokines and of growth factors leading to necrosis of hepatocytes and proliferation of fibroblasts, resulting in the development of fibrosis/cirrhosis. Furthermore, a high turnover of hepatocytes can confer to the host DNA certain mutations that are probably responsible for their malignant transformation[41-44]. In view of these crucial considerations regarding various factors in chronic active HBV infection with possible involvement in the development of HCC, it is reasonable that several studies have tried to evaluate the effect of antiviral treatment of CHB not only regarding prevention of disease progression to cirrhosis and its decompensation but also in terms of possible prevention from development of hepatocellular carcinoma and death, although HBV-DNA becomes integrated into the genome of hepatocytes of the patient, from the early phases of HBV infection, probably years before the start of treatment[45,46].

**TREATMENT OF CHB**

Currently, the great majority of patients with CHB are treated worldwide with NAs. Finite courses of treatment with pegylated interferon (IFN) for 1 or 2 years also represent first line therapies both for HBeAg positive and HBeAg-negative patients and should be first applied to all patients eligible for therapy, provided, of course, that there are no contraindications and that IFN is tolerated without major side effects. The aim of such therapies is to achieve sustained virological response (SVR) and subsequent HBsAg loss representing the closest to cure outcome of chronic HBV infection[46]. However, the frequency of such an effect, achieved even on the basis of response guided treatment, does not exceed 20% or at maximum 30%[47-49]. Thus, it is understandable why currently long-term NA therapy has turned out to be the number one first choice treatment of CHB. Prerequisite for the success of such long-term therapies is the use of compounds of robust antiviral potency and of high barrier to HBV resistance as are the current first line NAs Entecavir (ETV) and Tenofovir (TDF).

Long-term NA therapies reduce the incidence of unfavorable long-term outcomes of CHB (cirrhosis, decompensation of cirrhosis, liver transplantation) and can even lead to regression of advanced fibrosis/cirrhosis[50-53]. Thus, long-term therapy with these compounds represents a first-line recommendation of the treatment guidelines of the AASLD, EASL and APASL[46,54,55]. After all, the ultimate goal of therapy in CHB is to improve the quality of life and the survival of patients by preventing the progression of the underlying liver disease to cirrhosis, to decompensated cirrhosis, end-stage liver disease, to development of HCC and death[46].

**THE EFFECT OF LONG-TERM TREATMENT WITH NAS ON THE DEVELOPMENT OF HCC**

***Lamivudine and adefovir dipivoxil***

Most data is derived from the application of lamivudine (LAM), the first NA used for the treatment of CHB. The story begun with a breakthrough Asian study published ten years ago, showing that a single pill can change the natural history of CHB[56]. This study is the only randomized controlled clinical trial comparing the efficacy of treatment with lamivudine versus placebo on disease progression in a large number (*n* = 651) of patients with CHB and advanced fibrosis or cirrhosis with 58% of them being HBeAg-positive. Though the study was planned for a maximum of five years, it was terminated prematurely after 32.4 mo, since the difference between treated and untreated control patients became obvious from the first year of therapy and it was considered unethical to continue treating with placebo patients with advanced liver disease. The lamivudine arm showed cumulative development of HCC of 3.9% *vs* 7.4% in the placebo arm (*P* = 0.047), yet the clinical benefits for disease progression and HCC development were lost when resistance to the drug was developed (11% in patients with resistance *vs* 5% in placebo treated patients). Moreover, when HCC cases diagnosed in the first year of the trial were excluded, only a marginal difference could be detected (*P* = 0.052). It has, however, been implied, that if the study had continued for longer, then the difference in favor of lamivudine would have been more profound.

Following this initial study, many more were conducted. Most of them have been retrospective with matched historical controls and all of them showed that lamivudine reduced statistically the risk for disease progression to cirrhosis and for development of HCC[57-60]. However, different methods of HBV-DNA assay with different limits in its detection were used in these studies, many patients had YMDD mutations and in some studies there was no match with untreated controls for HBV-DNA levels, HBeAg positivity, and duration of follow-up or age. These limitations could have possibly resulted in downgrading of the differences between the treated and control patients[57-60].

During the last eight years, one meta-analysis[61] and one systematic review[62] were published dealing with the crucial debate of whether nucleos(t)ide analogs and mainly lamivudine treatment of chronic hepatitis B significantly reduces the risk of hepatocellular carcinoma both in cirrhotic and in non-cirrhotic patients[61,62].

The meta-analysis included 5 studies[56-60] with 1267 patients treated mostly with LAM and compared them with 1022 untreated ones[61]. Overall, with the use of LAM the incidence of HCC was reduced by 78% (2.5% *vs* 11.7%, RR = 0.22, *P* < 0.001). The risk of HCC was significantly reduced in cirrhotics (3.9% *vs* 22.4%, RR = 0.17, *P* = 0.020), non-cirrhotics (1.8% *vs* 8%, RR = 0.21, *P* < 0.001), both in patients who developed drug resistance (3.3% *vs* 6.4%, RR = 0.52, *P* = 0.04) or not: *P* = 0.008 and in HBeAg (+) (1.7% *vs* 7.9%, *P* < 0.001) patients while in HBeAg (-) patients the difference was not statistically significant (3% *vs* 10%, *P* = 0.06).

The systematic review included 21 studies with 3881 patients treated mainly with lamivudine (and/or adefovir, ADV) and 534 untreated ones[62]. Of the studied patients, 33% were cirrhotics and 49% were HBeAg (+), while sixteen studies included treatment-naïve patients and five included patients with lamivudine resistance. Three studies followed-up both treated and untreated patients[56-58] and their analysis showed that treated patients had a significantly lower risk for HCC (2.8% *vs* 6.4%, *P* = 0.003) than untreated ones, while this benefit remained the same whether being in virological remission (2.5% *vs* 6.4%, *P* = 0.015) or not (2.8% *vs* 6.4%, *P* = 0.016). Patients under remission had a lower risk for HCC compared to those with breakthrough or without response to treatment (2.3% *vs* 7.5%, *P* < 0.001). Moreover, if remission was accomplished with the initial treatment, then the risk for HCC was lower compared to the risk in patients who accomplished remission under rescue therapy with adefovir (2.3% *vs* 5.9%, *P* = 0.003). As expected, treatment naïve patients with cirrhosis had higher HCC incidence than non-cirrhotic ones (10.8% *vs* 0.5%, *P* < 0.001), while the risk for HCC was higher in older (≥ 50 years old) (6% *vs* 2.8%, *P* < 0.001) and HBeAg (-) patients (5.5% *vs* 0.5%, *P* < 0.001) than in younger (< 50 years old) and HBeAg (+) ones, respectively. In patients with lamivudine resistance, those with cirrhosis had a higher risk for HCC compared to non-cirrhotic ones (17.6% *vs* 0%, *P* < 0.001). Rescue treatment with adefovir in patients who developed biochemical breakthrough did not appear to reduce the risk for HCC compared to patients who remained untreated without remission (8.8% *vs* 5.6%, *P* = 0.466).

Therefore, lamivudine treatment with/or without rescue treatment with adefovir seems to reduce but not eliminate the risk for HCC. However, a more recent study[63] revealed that even on-treatment virological remission achieved in cirrhotic patients may not lead to reduction of the incidence of HCC, while another study showed significant reduction in the risk for HCC with on-treatment response[64]. Nevertheless, it must be taken into account that most studies of lamivudine treatment with/without rescue treatment with adefovir conducted in the past suffer from several drawbacks: (1) Usually they are non-randomized trials without pretreatment stratification for age, gender, severity of disease and other HCC predictors; (2) Surrogate endpoints of response, such as HBeAg seroconversion or biochemical responses have been applied and not hard endpoints, such as reversal of cirrhosis or prevention from HCC; (3) Because of their design they were completed while serum HBV-DNA was still detectable in many cases; (4) Probably the length of the follow-up was too short to detect a change in the risk for HCC; and (5) HBV resistance to NAs a factor linked with increased risk for HCC was most frequently encountered in the treatment with lamivudine.

Following lamivudine and adefovir, many steps forward were made in the therapy of chronic hepatitis B with the newer nucleos(t)ide analogues Entecavir and Tenofovir of high potency and high barrier to HBV resistance and several studies have accumulated on the effect of long-term NA therapy in the prevention of development of HCC in the course of chronic HBV infection.

***Entecavir, Telbivudine, Tenofovir***

There are 3 third generation anti-HBV NAs approved for the treatment of CHB: Entecavir (ETV) approved in 2005, Telbivudine (LdT) approved in 2007 and Tenofovir (TDF) approved in 2008. All 3 are highly potent anti-HBV compounds but the barrier of resistance of LdT is low and thus for the time being only therapies with ETV and TDF are considered as first line ones. Since ETV has been licensed and used longer than tenofovir, especially in Asian countries, there is more information regarding the potential benefit of the former than of the latter in CHB as well as on its comparison to lamivudine. Most studies with these compounds have been conducted in Asiatic populations but significant evidence has now accumulated regarding Tenofovir and Entecavir also in Western countries.

In a retrospective study from Japan the outcome of 316 patients under ETV treatment was compared to that of an equal number of historical untreated controls and of 182 patients under LAM treatment without rescue therapy upon development of HBV resistance[65]. The cohort of ETV treated patients had a 63% reduction of HCC incidence compared to untreated ones (cumulative HCC incidence at 5 years 3.7% *vs* 13.7%, *P* < 0.001), which was most obvious in cirrhotic patients (7% *vs* 39%, *P* < 0.001), but not in non-cirrhotic ones (2.5% *vs* 3.6%, *P* = 0.44). Moreover, reduction in the incidence of HCC under ETV treatment was greater than in the non-rescued LAM group of cirrhotic patients (7% *vs* 22%, *P* = 0.043), but again not in the non-cirrhotics (2.5% *vs* 4.9%, *P* > 0.05). Nevertheless, the advantage of entecavir over lamivudine could not be proved in two other studies, one again from Japan and the other from Greece as well as in a recent meta-analysis[66-68].

In the Asian study, 129 naïve patients (22% cirrhotics) under ETV therapy were prospectively followed (median F-UP: 4.25 years) and compared with 127 patients (27% cirrhotics) under LAM treatment[66]. The cumulative 5-year risk for HCC was 12.4 in both groups, yet patients under LAM therapy who developed resistance (60/127, 47%) had statistically higher HCC risk compared to those without resistance (*P* = 0.035).

Similar to the aforementioned results are those of a multicenter Greek study, published three years later, in which 321 HBeAg (-) patients (86% naïve-14% treatment experienced, 25% cirrhotics) under ETV treatment were followed (median F-UP: 30 mo) and were compared with a known cohort of 818 patients under LAM treatment rescued with adefovir (ADV) upon development of HBV resistance (26% cirrhotics)[67]. In this study, only a trend towards lower 5-year cumulative HCC incidence in the ETV-group was shown compared to the LAM-group (4.8% *vs* 5.6%, *P* = 0.096), while in multivariate analysis, HCC development was statistically associated with older age, male gender and presence of cirrhosis but not with the type of initial treatment.

In a most recent study from Asia, 5374 patients either under LAM or ETV treatment (3374 and 2000 patients with median treatment duration 6.1 and 2.6 years respectively from 1999 until 2011) were retrospectively analyzed (median F-UP for the LAM and ETV treated patients: 3.1 and 8.7 years respectively)[69]. Importantly, ETV-treated cirrhotic patients had statistically lower relative risk for death or liver transplantation compared to LAM-treated ones. However, no difference was found between the two groups regarding the risk for development of HCC.

Conflicting is the information derived from a large retrospective nationwide cohort study conducted in Taiwan with 21595 patients treated for at least 90 d with LAM, ETV or telbivudine[70]. The results were compared with those of 21595 controls treated with only an hepatoprotective agent. Treated patients had a significantly lower 7-year incidence of HCC compared to controls (7.32% *vs* 22.7%, *P* < 0.001) and the difference was more obvious in young patients without cirrhosis as well as in those without diabetes mellitus.

Moreover, in a roll-over study of registration trials of tenofovir (TDF) in HBeAg (+) and HBeAg (-) patients, using the REACH-B scoring system for HCC development, a 55% reduction in HCC risk was shown among 641 patients who completed 6 years of treatment and in cirrhotic patients after the 5th year of treatment, while no difference could be detected in the non-cirrhotic ones[71].

Yet, while a statistical significant difference in the risk for development of HCC between treated and untreated patients has been clearly documented in many Asiatic studies, this has not been the case with studies in Caucasian population, in which the difference in the risk for HCC between treated and untreated patients has been only marginal[63,67,72-74].

Thus, in agreement with the results of the Greek studies[63,67], an Italian one of long-term treatment with ETV showed an annual development of HCC of 0.8% in non-cirrhotic patients and of 2.6% in the cirrhotic ones. These rates are not statistically different from those in untreated historical controls[16,72].

Moreover, similar are the results in European multicenter studies published this year. A total of 744 patients from 11 European centers were included in the first of the studies (42% Caucasian, 29% Asian, 77% naïve, 22% cirrhotic)[73]. They were all treated with entecavir and after a median follow-up of 167 wk, 14 patients developed HCC with 64% of them being cirrhotics. The 5-year cumulative HCC incidence was 2.1% for non-cirrhotic patients and 10.9% for cirrhotic ones (*P* < 0.001), with HCC incidence being higher in older patients and those with lower baseline platelet counts.

In another large European multicenter, retrospective cohort study 1,666 CHB patients (85% HBeAg (-), 67% with CHB, 29% cirrhotics and 3% with decompensated cirrhosis), from 7 centers treated with ETV or TDF were followed-up for a median period of 39 mo[74]. HCC developed in 71 (4.3%) of the 1666 patients with an incidence rate of 1.37 new HCC cases per 100 patients per year. The cumulative probability of HCC was 1.3% at the 1st year, 3.4% at the 3rd year and 8.7% at the 5th year after the onset of treatment., Again these findings are not different from those on the risk of HCC development among published untreated or lamivudine treated cohorts of patients[16,56,60,62]. Virological remission was achieved in 92% of the patients and it was not found to be significantly associated with the probability of HCC development. In the multivariate analysis, the factors positively associated with development of HCC were age, severity of liver disease and platelet count at the start of treatment[74]. The summary of the mentioned studies and meta-analyses is outlined in Table 1.

Furthermore, the last two studies evaluated the recently developed scoring systems (GAG-HCC, CU-HCC and REACH-B scores) in population of Caucasian patients[73,74]. These scores, based on characteristics of the virus and of the patients, were validated and used to predict HCC development in treated Asian patients[75-78], Table 2. In both studies, the predictability of these scoring systems was poor to modest for the overall Caucasian population of patients, showing that a considerable proportion of individuals, particularly Caucasians, who will develop HCC, cannot be identified by these scoring systems. Hence, their clinical utility especially in Caucasians remains debatable.

The topic of the risk for development of hepatocellular carcinoma in chronic hepatitis B patients and its possible reduction by antiviral treatment has been widely covered in the last AASLD meeting of 2014 in Boston with several oral presentations and posters[79-88]. From an overall analysis of these studies it can be deduced that antiviral therapy is associated with reduction of the risk for development of HCC. However, the risk still remains high, particularly in males of older age and in patients with cirrhosis. Therefore continuous surveillance is imperative in all CHB patients regardless of the outcome of anti-HBV therapy even if HBsAg has been cleared and anti-HBs have developed. Irrespective of virological remission induced by antiviral treatment, CHB patients and especially those with the highest risk- men>50 and cirrhotics - should continue to be surveilled, according to the existing recommendations[45]. Moreover, CHB patients whether with or without cirrhosis, who experience HBsAg loss with or without seroconversion to anti-HBs, continue to remain at risk for HCC and therefore, their surveillance should also be continued[89,90].

Moreover, loss of HBsAg at the age ≥ 50 years was found to be an independent predictor of development of HCC.

**CONCLUSION**

In view of the above pooled data from studies of more than ten years, it is reasonable to conclude that treatment of chronic hepatitis B with oral antiviral agents, especially the first line ones entecavir and tenofovir, definitely prolongs survival and changes the natural history of the disease, with significant reduction of the incidence of cirrhosis, decompensation of cirrhosis, and end-stage liver disease leading to death or liver transplantation[52,53,69,91,92]. Yet, the potential benefits of antiviral treatment in the reduction of the risk for development of HCC have not been very impressive. A reduction but not elimination in its incidence has been documented even in patients who achieved loss of HBsAg. This has an impact also in the waiting lists of liver transplantation. Thus, in the United States patients enlisted for transplantation for complications of CHB, a 42% relative reduction of end-stage liver disease and a concomitant 72% relative increase of HCC are recorded. To a significant extent, these changes have been secondary to antiviral treatment[93]. Furthermore, in Europe the percentage of HBV cirrhotics transplanted for consequences of viral hepatitis has been reduced from 24% to 16% of the total[92].

The self-contradictory finding that antiviral treatment in CHB can prevent clinical decompensation while it does not seem to affect considerably the development of HCC, is due on the one hand to the prolongation of survival without clinical consequences of hepatic decompensation, and on the other hand to the ongoing extended exposure of the patients to the harmful effects of integrated HBV sequences.

Hopefully, in the years to come, new anti-HBV therapies may manage to timely and completely eradicate HBV from the host genome and therefore may also manage to eliminate the risk for development of HCC in CHB[94].

**REFERENCES**

1 **Ferlay J**, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010; **127**: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc25516]

2 **Ferlay J**, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; **136**: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]

3 **Siegel R**, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013; **63**: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]

4 **Forner A**, Llovet JM, Bruix J. Hepatocellular carcinoma. *Lancet* 2012; **379**: 1245-1255 [PMID: 22353262 DOI: 10.1016/S0140-6736]

5 **Sherman M**. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. *Semin Liver Dis* 2010; **30**: 3-16 [PMID: 20175029 DOI: 10.1055/s-0030-1247128]

6 **Beasley RP**, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. *Lancet* 1981; **2**: 1129-1133 [PMID: 6118576]

7 **Sherlock S**, Fox RA, Niazi SP, Scheuer PJ. Chronic liver disease and primary liver-cell cancer with hepatitis-associated (Australia) antigen in serum. *Lancet* 1970; **1**: 1243-1247 [PMID: 4192492]

8 **Hadziyannis SJ**, Merikas GE, Afroudakis AP. Hepatitis-associated antigen in chronic liver disease. *Lancet* 1970; **1**: 100 [PMID: 4193331]

9 **Sherlock S**. Long-incubation (virus B, HAA-associated) hepatitis. *Gut* 1972; **13**: 297-307 [PMID: 4113680]

10 **Smith JB**, Blumberg BS. Viral hepatitis, postnecrotic cirrhosis, and hepatocellular carcinoma. *Lancet* 1969; **2**: 953 [PMID: 4186610]

11 **Blumberg BS**. Primary and secondary prevention of liver cancer caused by HBV. *Front Biosci* (Schol Ed) 2010; **2**: 756-763 [PMID: 20036981]

12 **Hadziyannis SJ**. Chronic viral hepatitis. *Clin Gastroenterol* 1974; **3**: 391-408 [PMID: 4608655]

13 **Hadziyannis SJ**, Karvountzis GG, Manesis E, Merikas GE. Letter: Hepatitis-B core antigen and antibody in primary liver cancer. *Lancet* 1975; **2**: 418-419 [PMID: 51233]

14 **Hadziyannis SJ**. Hepatocellular carcinoma and type B hepatitis. *Clin Gastroenterol* 1980; **9**: 117-134 [PMID: 6249525]

15 **Shafritz DA**, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. *N Engl J Med* 1981; **305**: 1067-1073 [PMID: 6268980]

16 **Fattovich G**, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. *J Hepatol* 2008; **48**: 335-352 [PMID: 18096267 DOI: 10.1016/j.jhep2007.11.011]

17 **Fattovich G**, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, Realdi G, Ruol A. Natural history and prognostic factors for chronic hepatitis type B. *Gut* 1991; **32**: 294-298 [PMID: 2013423]

18 **Ikeda K**, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. *J Hepatol* 1998; **28**: 930-938 [PMID: 9672166]

19 **Papatheodoridis GV**, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. *J Hepatol* 2001; **34**: 306-313 [PMID: 11281561]

20 **Ladep NG**, Lesi OA, Mark P, Lemoine M, Onyekwere C, Afihene M, Crossey MM, Taylor-Robinson SD. Problem of hepatocellular carcinoma in West Africa. *World J Hepatol* 2014; **6**: 783-792 [PMID: 25429316]

21 **Chen CJ**, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA* 2006; **295**: 65-73 [PMID: 16391218 DOI: 10.1001/jama]

22 **Park BK**, Park YN, Ahn SH, Lee KS, Chon CY, Moon YM, Park C, Han KH. Long-term outcome of chronic hepatitis B based on histological grade and stage. *J Gastroenterol Hepatol* 2007; **22**: 383-388 [PMID: 17295771]

23 **Shimizu I**. Impact of oestrogens on the progression of liver disease. *Liver Int* 2003; **23**: 63-69 [PMID: 12640729]

24 **Fattovich G**, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterology* 2004; **127**: S35-S50 [PMID: 15508101]

25 **Yu MW**, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, Chen PJ, Hsiao TJ, Lee PH, Chen CJ. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. *J Natl Cancer Inst* 2000; **92**: 1159-1164 [PMID: 10904089]

26 **Iloeje UH**, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. *Gastroenterology* 2006; **130**: 678-686 [PMID: 16530509]

27 **Chen G**, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. *Am J Gastroenterol* 2006; **101**: 1797-1803 [PMID: 16817842]

28 **Yu MW**, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, Shih WL, Kao JH, Chen DS, Chen CJ. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. *J Natl Cancer Inst* 2005; **97**: 265-272 [PMID: 15713961]

29 **Chan HL**, Hui AY, Wong ML, Tse AM, Hung LC, Wong VW, Sung JJ. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. *Gut* 2004; **53**: 1494-1498 [PMID: 15361502]

30 **Kao JH**, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. *Gastroenterology* 2003; **124**: 327-334 [PMID: 12557138]

31 **Liu CJ**, Chen BF, Chen PJ, Lai MY, Huang WL, Kao JH, Chen DS. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. *J Infect Dis* 2006; **194**: 594-599 [PMID: 16897657]

32 **Donato F**, Gelatti U, Limina RM, Fattovich G. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. *Oncogene* 2006; **25**: 3756-3770 [PMID: 16799617]

33 **Jee SH**, Ohrr H, Sull JW, Samet JM. Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea. *J Natl Cancer Inst* 2004; **96**: 1851-1856 [PMID: 15601641]

34 **Fattovich G**, Boscaro S, Noventa F, Pornaro E, Stenico D, Alberti A, Ruol A, Realdi G. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. *J Infect Dis* 1987; **155**: 931-935 [PMID: 3559292]

35 **Tamura I**, Kurimura O, Koda T, Ichimura H, Katayama S, Kurimura T, Inaba Y. Risk of liver cirrhosis and hepatocellular carcinoma in subjects with hepatitis B and delta virus infection: a study from Kure, Japan. *J Gastroenterol Hepatol* 1993; **8**: 433-436 [PMID: 8218990]

36 **del Olmo JA**, Serra MA, Rodríguez F, Escudero A, Gilabert S, Rodrigo JM. Incidence and risk factors for hepatocellular carcinoma in 967 patients with cirrhosis. *J Cancer Res Clin Oncol* 1998; **124**: 560-564 [PMID: 9829860]

37 **Tsai JF**, Jeng JE, Ho MS, Chang WY, Hsieh MY, Lin ZY, Tsai JH. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. *Br J Cancer* 1997; **76**: 968-974 [PMID: 9328161]

38 **Ming L**, Thorgeirsson SS, Gail MH, Lu P, Harris CC, Wang N, Shao Y, Wu Z, Liu G, Wang X, Sun Z. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. *Hepatology* 2002; **36**: 1214-1220 [PMID: 12395332]

39 **Tseng TC**, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. *Gastroenterology* 2012; **142**: 1140-1149.e3; quiz e13-14 [PMID: 22333950 DOI: 10.1053/j.gastro]

40 **Tseng TC**, Liu CJ, Chen CL, Yang HC, Su TH, Wang CC, Yang WT, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers. *J Infect Dis* 2013; **208**: 584-593 [PMID: 23656977 DOI: 10.1093/infdis/jit]

41 **Neuveut C**, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. *J Hepatol* 2010; **52**: 594-604 [PMID: 20185200 DOI: 10.1016/j.jhep.2009.10.033]

42 **Tan YJ**. Hepatitis B virus infection and the risk of hepatocellular carcinoma. *World J Gastroenterol* 2011; **17**: 4853-4857 [PMID: 22171125 DOI: 10.3748/wjg.v17.i44.4853]

43 **Guerrieri F**, Belloni L, Pediconi N, Levrero M. Molecular mechanisms of HBV-associated hepatocarcinogenesis. *Semin Liver Dis* 2013; **33**: 147-156 [PMID: 23749671]

44 **Budhu A**, Wang XW. The role of cytokines in hepatocellular carcinoma. *J Leukoc Biol* 2006; **80**: 1197-1213 [PMID: 16946019 DOI: 10.1189/jlb]

45 **European Association For The Study Of The Liver.** EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2012; **56**: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep]

46 **European Association For The Study Of The Liver.** EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. *J Hepatol* 2012; **57**: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep2012.02.010]

47 **van Zonneveld M**, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, Schalm SW, Janssen HL. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. *Hepatology* 2004; **39**: 804-810 [PMID: 14999700]

48 **Moucari R**, Korevaar A, Lada O, Martinot-Peignoux M, Boyer N, Mackiewicz V, Dauvergne A, Cardoso AC, Asselah T, Nicolas-Chanoine MH, Vidaud M, Valla D, Bedossa P, Marcellin P. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. *J Hepatol* 2009; **50**: 1084-1092 [PMID: 19376603]

49 **Marcellin P**, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. *Gastroenterology* 2009; **136**: 2169-2179.e1-4 [PMID: 19303414 DOI: 10.1053/j.gastro.2009.03.006]

50 **Chang TT**, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. *Hepatology* 2010; **52**: 886-893 [PMID: 20683932 DOI: 10.1002/hep.23785]

51 **Marcellin P**, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. *Lancet* 2013; **381**: 468-475 [PMID: 23234725 DOI: 10.1016/S0140-6736(12)61425-1]

52 **Liaw YF**. Impact of therapy on the long-term outcome of chronic hepatitis B. *Clin Liver Dis* 2013; **17**: 413-423 [PMID: 23905813 DOI: 10.1016/j.cld.2013.05.005]

53 **Zoutendijk R**, Reijnders JG, Zoulim F, Brown A, Mutimer DJ, Deterding K, Hofmann WP, Petersen J, Fasano M, Buti M, Berg T, Hansen BE, Sonneveld MJ, Wedemeyer H, Janssen HL. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. *Gut* 2013; **62**: 760-765 [PMID: 22490523 DOI: 10.1136/gutjnl-2012-302024]

54 **Lok AS**, McMahon BJ. Chronic hepatitis B: update 2009. *Hepatology* 2009; **50**: 661-662 [PMID: 19714720 DOI: 10.1002/hep.23190]

55 **Liaw YF**, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, Amarapurkar D, Cooksley G, Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA, Sollano JD, Suh DJ, Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. *Hepatol Int* 2012; **6**: 531-561 [DOI: 10.1007/s12072-012-9365-4]

56 **Liaw YF**, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. *N Engl J Med* 2004; **351**: 1521-1531 [PMID: 15470215 DOI: 10.1056/NEJMoa033364]

57 **Yuen MF**, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, Wong BC, Fung J, Yuen JC, Lai CL. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. *Antivir Ther* 2007; **12**: 1295-1303 [PMID: 18240869]

58 **Matsumoto A**, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H, Omata M, Okita K, Hayashi N, Okanoue T, Iino S, Tanikawa K. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. *Hepatol Res* 2005; **32**: 173-184 [PMID: 16024289]

59 **Eun JR**, Lee HJ, Kim TN, Lee KS. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. *J Hepatol* 2010; **53**: 118-125 [PMID: 20471129 DOI: 10.1016/j.jhep.2010.02.026]

60 **Papatheodoridis GV**, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, Tzourmakliotis D, Manesis E, Hadziyannis SJ. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. *Hepatology* 2005; **42**: 121-129 [PMID: 15962291]

61 **Sung JJ**, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. *Aliment Pharmacol Ther* 2008; **28**: 1067-1077 [PMID: 18657133 DOI: 10.1111/j.1365-2036.2008.03816.x]

62 **Papatheodoridis GV**, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. *J Hepatol* 2010; **53**: 348-356 [PMID: 20483498 DOI: 10.1016/j.jhep.2010.02.035]

63 **Papatheodoridis GV**, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. *Gut* 2011; **60**: 1109-1116 [PMID: 21270118 DOI: 10.1136/gut.2010.221846]

64 **Kurokawa M**, Hiramatsu N, Oze T, Yakushijin T, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Iio S, Doi Y, Yamada A, Oshita M, Kaneko A, Mochizuki K, Hagiwara H, Mita E, Ito T, Inui Y, Katayama K, Yoshihara H, Imai Y, Hayashi E, Hayashi N, Takehara T. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection. *J Gastroenterol* 2012; **47**: 577-585 [PMID: 22231575]

65 **Hosaka T**, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. *Hepatology* 2013; **58**: 98-107 [PMID: 23213040 DOI: 10.1002/hep.26180]

66 **Kobashi H**, Miyake Y, Ikeda F, Yasunaka T, Nishino K, Moriya A, Kubota J, Nakamura S, Takaki A, Nouso K, Yamada G, Yamamoto K. Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. *Hepatol Res* 2011; **41**: 405-416 [PMID: 21435126 DOI: 10.1111/j.1872-034X.2011.00785.x]

67 **Papatheodoridis GV**, Manolakopoulos S, Touloumi G, Nikolopoulou G, Raptopoulou-Gigi M, Gogos C, Vafiadis-Zouboulis I, Karamanolis D, Chouta A, Ilias A, Drakoulis C, Mimidis K, Ketikoglou I, Manesis E, Mela M, Hatzis G, Dalekos GN. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort. *J Viral Hepat* 2015; **22**: 118-125 [PMID: 25040685 DOI: 10.1111/jvh.12283]

68 **Singal AK**, Salameh H, Kuo YF, Fontana RJ. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. *Aliment Pharmacol Ther* 2013; **38**: 98-106 [PMID: 23713520 DOI: 10.1111/apt.12344]

69 **Lim YS**, Han S, Heo NY, Shim JH, Lee HC, Suh DJ. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. *Gastroenterology* 2014; **147**: 152-161 [PMID: 24583062 DOI: 10.1053/j.gastro.2014.02.033]

70 **Wu CY**, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, Wu C, Wu JC. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. *Gastroenterology* 2014; **147**: 143-151.e5 [PMID: 24704525 DOI: 10.1053/j.gastro.2014.03.048]

71 **Kim WR**, Berg T, Loomba R, Aguilar Schall R, Dinh P, Yee LJ, Martins EB, Flaherty JF, Gurel S, Buti M, Marcellin P. Long Term Tenofovir Disoproxil Fumarate (TDF) Therapy and the Risk of Hepatocellular Carcinoma. *J Hepatol* 2013; **58**: S19 [DOI: 10.1016/S0168-8278(13)60045-8]

72 **Lampertico P**, Soffredini R, Vigan M, Minola E, Cologni G, Rizzi M, Zaltron S, Vavassori A, Castelli F, Angeli E, Gubertini GA, Magni C, Rizzardini G, Testa A, D’Offizi G, Vinci M, Pinzello G, Fatta E, Fargion S, Colombo S, Fracassetti O, Del Poggio P, Coco B, Brunetto MR, Andreoletti M, Colli A, Fasano M, Santantonio T, Colloredo G, Pasulo L, Fagiuolli S, Colombo AE, Bellati G, Milanese M, Strazzabosco M, Pozzi M, Terreni N, Spinzi G, Quagliuolo M, Borzio M, Lunghi G, Facchetti F, Invernizzi F, Colombo M. 5-year entecavir treatment in NUC-naïve, field-practice patients with chronic hepatitis B showed excellent viral suppression and safety profile but no prevention of HCC in cirrhotics. *J Hepatol* 2013; **58**: S306-307

73 **Arends P,** Sonneveld M, Zoutendjik R, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Reijnders J, Oo Ye, Petersen J, van Bömmel F, de Knegt R, Santantonio T, Berg T, Welzel T, Wedemeyer H, Buti M, Pradatt P, Zoulim F, Hansen B, Janssen H, for the VIRGIL Surveillance Study Group. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. *Gut* 2014; Epub ahead of print [PMID: 25011935 DOI: 10.1136/gutjnl-2014-307023]

74 **Papatheodoridis GV**, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, Sypsa V, Manolakopoulos S, Mangia G, Gatselis N, Keskın O, Savvidou S, Hansen BE, Papaioannou C, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. *J Hepatol* 2015; **62**: 363-370 [PMID: 25195548 DOI: 10.1016/j.jhep2014.08.045]

75 **Yuen MF**, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, But DY, Chan AO, Wong BC, Mizokami M, Lai CL. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. *J Hepatol* 2009; **50**: 80-88 [PMID: 18977053 DOI: 10.1016/j.jhep.2008.07.023]

76 **Wong VW**, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, Lui YY, Chan AT, Sung JJ, Yeo W, Chan HL, Mok TS. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. *J Clin Oncol* 2010; **28**: 1660-1665 [PMID: 20194845 DOI: 10.1200/JCO.2009.26.2675]

77 **Yang HI**, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, Ahn SH, Chen CJ, Wong VW, Seto WK. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. *Lancet Oncol* 2011; **12**: 568-574 [PMID: 21497551 DOI: 10.1016/S1470-2045(11)70077-8]

78 **Wong GL**, Chan HL, Chan HY, Tse PC, Tse YK, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Wong VW. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. *Gastroenterology* 2013; **144**: 933-944 [PMID: 23415803 DOI: 10.1053/j.gastro.2013.02.002]

79 **Lin D**, Nguyen NH, Hoang J, Vu VD, Trinh HN, Li J, Zhang JQ, Nguyen HA, Nguyen K, Nguyen MH. Incidence of hepatocellular carcinoma (HCC) in a US cohort of chronic hepatitis B (CHB) patients by age, gender, cirrhosis and antiviral treatment status. *Hepatology* 2014; **60** (S1): 315A

80 **Papatheodoridis GV**, Dalekos GN, Sypsa V, Yurdaydin C, Buti M, Goulis I, Chi H, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, Hansen BE, Vlachogiannakos J, Galanis K, Idilman R, Colombo M, Esteban R, Janssen H, Lampertico P. Timing of hepatocellular (HCC) development and predictability of a modified PAGE-B risk score in Caucasian chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir (TDF). *Hepatology* 2014; **60** (S1): 316A

81 **Wu Y,** Li X, Huang M, Lin G, Chen S, Shi H, Jie Y, Li X-H, Yang F, Zhang M, Ao Y, Pang Y, Chong Y. Occurrence of hepatocellular carcinoma is comparable in chronic HBV infectors treated with different nucleos (t)ide analogues: A 6-year retro- and prospective real world cohort study. *Hepatology* 2014; **60** (S1): 882A-883A

82 **House H**, Selvapatt N, Brown A. A retrospective review of hepatocellular carcinoma surveillance in 3 United Kingdom teaching hospitals. *Hepatology* 2014; **60** (S1): 856A

83 **Kim GA**, Lee HC, Ha Y, Park EJ, An J. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance. *Hepatology* 2014: **60** (S1): 972A

84 **Chen CH**, Lee CM, Hu TH, Hung CH, Wang JH, Lu SN. The role of hepatitis B surface antigen quantification predict HBV reactivation after discontinuation of nucleos(t)ide analogs treatment in chronic hepatitis B patients with cirrhosis. *Hepatology* 2014; **60** (S1): 1103A

85 **Ahn J,** Lim JK, Lee H, Pan CQ, Nguyen MH, Trinh HN, Tran TT, Chu D, Min A, Do ST, Woog J, Mannalithara A, Lok AS, Kim WR. Incidence of hepatocellular carcinoma in a national cohort of chronic hepatitis B patients on long term entecavir treatment-the ENUMERATE study. *Hepatology* 2014; **60** (S1): 1099A

86 **Kim GA**, Han S, An J, Lim YS. Risk of hepatocellular carcinoma among treated patients with chronic hepatitis B vs chronic hepatitis C. *Hepatology* 2014; **60** (S1): 1092A

87 **Haang JK**, Nguyen NH, Lin d, Vu VD, Trinh HN, Li J, Zhang JQ, Nguyen HA, Nguyen K, Nguyen MH. Incidence of hepatocellular carcinoma (HCC) in non-cirrhotic chronic hepatitis B (CHB) patients with low ALT levels in a multicenter US cohort. *Hepatology* 2014; **60** (S1): 1088A

88 **Yasunaka T**, Ikeda F, Takaki A, Seno T, Takaguchi K, Yamamoto K. Entecavir reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis B. *Hepatology* 2014; **60** (S1): 1096A

89 **Simonetti J**, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, Williams J, Livingston SE. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. *Hepatology* 2010; **51**: 1531-1537 [PMID: 20087968 DOI: 10.1002/hep.23464]

90 **Yuen MF**, Wong DK, Fung J, Ip P, But D, Hung I, Lau K, Yuen JC, Lai CL. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. *Gastroenterology* 2008; **135**: 1192-1199 [PMID: 18722377 DOI: 10.1053/j.gastro.2008.07.008]

91 **Li CZ**, Cheng LF, Li QS, Wang ZQ, Yan JH. Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. *World J Gastroenterol* 2013; **19**: 6849-6856 [PMID: 24187460 DOI: 10.3748/wjg.v19.i40.6849]

92 **Burra P**, Germani G, Adam R, Karam V, Marzano A, Lampertico P, Salizzoni M, Filipponi F, Klempnauer JL, Castaing D, Kilic M, Carlis LD, Neuhaus P, Yilmaz S, Paul A, Pinna AD, Burroughs AK, Russo FP. Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. *J Hepatol* 2013; **58**: 287-296 [PMID: 23099188 DOI: 10.1016/j.jhep.2012.10.016]

93 **Kim WR**, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. *Gastroenterology* 2009; **137**: 1680-1686 [PMID: 19632234 DOI: 1053/j.gastro.2009.07.047]

94 **Boettler T**, Moradpour D, Thimme R, Zoulim F. Bridging basic science and clinical research - the EASL Monothematic Conference on Translational Research in Viral Hepatitis. *J Hepatol* 2014; **61**: 696-705 [PMID: 24845610 DOI: 10.1016/j.jhep.2014.05.016]

**P-Reviewer:** Aghakhani A, Gong ZJ, Said ZNA **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 Summary of studies and meta-analyses evaluating the effect of antiviral therapy on the incidence of hepatocellular carcinoma in chronic hepatitis B patients**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Total no. of patients, trx/untrx** | **Type of study** | **NUC used** | **F-up****(median)****trx/untrx** | **Cumulative incidence of HCC****% trx/ %untrx** | **RR****or SIR****(95%CI)** | ***P* value** |
| Liaw *et al*[56],2004 | 436/215 | RCT, Prospective | LAM *vs* placebo | 2.7 yr | 3.9/7.4 | RR: 0.49 | 0.047 |
| Yuen *et al*[57], 2007 | 142/104 | Prospective | LAM | 8.2 yr | 0.7 /2.4 | RR: 0.20CI: 0.03-2.76) | 0.005 |
| Matsumoto *et al*[58], 2005 | 657/2138 | Retrospective | LAM*vs* placebo | 2.7/5.3 yr | 1.1/13.3 | RR: 0.08(CI: 0.03-0.22) | < 0.001 |
| Eun *et al*[59], 2010 | 872/699 | Retrospective | LAM *vs* placebo | 5.1 ± 2.7/6.1± 4.3 yr | Annual incidence:0.95 (VR with LAM)/4.1 (controls)/ 2.18 (R) | RR: 0.14(0.006-0.34) | 0.005(CIR),0.123(non-CIR) |
| Papatheodo- ridis *et al*[60], 2005 | 201/195 | Retrospective | LAM, LAM +ADV | 3.8 ± 1.4 yr | 2.48/7.7 | RR: 0.32(0.12-0.87) | 0.01 |
| Papatheodo- ridis *et al*[63], 2011 | 818 | Retrospective | LAM,ADV (add-on), switch to ADV or ETV upon R | 4.7 yr | 6% (2.5%/yr) | RR: 1 (VR)RR: 2.04(0.49-8.3)(no VR) | 0.322 |
| Kurokawa *et al*[64],2012 | 293 | Retrospective | LAM | 67.6 ± 27.4mo | 3 (CHB)/30 (CIR) |  |  |
| Hosaka *et al*[65], 2013 | 316 (ETV)/316 (untrx)/182 (LAM) | Retrospective | LAM, ETV | 5.4 yr | ETV/untrx3.7/13.7 | HCC reduction by 63% with ETVHR: 0.37(0.15-0.91) | < 0.001 |
| Kobashi *et al*[66], 2011 | ETV/LAM129/127 | Prospective | ETV,LAM | 4.25 yr | 12.4 |  | no difference ETV *vs* LAM |
| Papatheodo-ridis *et al*[67], 2014  | ETV/LAM321/818 | Retrospective | ETV,LAM | 30 mo | ETV/LAM4.8/5.6 |  | 0.096 |
| Lim *et al*[69], 2014 | LAM/ETV3374/2000 | Retrospective | LAM, ETV | LAM: 3.1 yrETV: 8.7 yr | 137/2000 (6.85)/234/3374 (6.9) | ETV/LAMHR: 1.01(CI: 0.8-1.24) | 0.95 |
| Wu *et al*[70], 2014 | 21595/21595 | Retrospective | LAM,ETV,LdT *vs* controls | 7 yr | 7.32/22.7 | CI: 6.77-7.87/22.1-23.3 | <0.001 |
| Kim *et al*[71], 2013 | 641 | Prospective roll-over | TDF | 5.52 yr | 56% reduction in CIR after the 5th year | SIR:0.55(0.32-0.94) at 5.52 years |  |
| Lampertico *et al*[72], 2013 | 418 | Retrospective/Prospective | ETV | 58 mo | 4( CHB)/13/(CIR) |  |  |
| Arends *et al*[73], 2014 | 744 | Prospective | ETV | 167 wk | Cumulative (5-year)2.1 (non-CIR)/10.9 (CIR) |  | CIR/non-CIR< 0.001 |
| Papatheodoridis *et al*[74], 2014  | 1666 | Retrospective | ETV,TDF | 39 mo | 1.3(1st year),3.4 (3d year),8.7 (5th year) |  | No difference from untrx published cohorts |
| Sung *et al*[61], 2008 | 5 studies1267/1022 | Meta-analysis | LAM |  |  | RR: 0.22(0.10-0.50)HBeAg(-):RR: 0.25(0.06-1.06) | < 0.001NS |
| Papatheodoridis *et al*[62], 2010  | 21 studies3881/534 | Systematicreview  | LAM |  | 2.8/6.4 |  | 0.003 |
| Singal *et al*[68], 2013 | 49 studies10025/3571 | Meta-analysis | LAM, ADV, ETV, LdT, TDF |  | Pooled HCC incidence rate:1.3(1.1-1.6)/100person-years | LAM *vs* untrxRR: 0.48(0.38-0.61) | < 0.001No difference between NUCs |

Trx: Treated; Untrx: Untreated; RR: Relative risk; SIR: Standardized incidence ratio); 95%CI: 95% confidence intervals; LAM: Lamivudine; VR: Virological remission; R: Resistance; CIR: Cirrhosis; ADV: Adefovir; CHB: Chronic hepatitis B; ETV: Entecavir; HR: Hazard ratio; LdT: Telbivudine; TDF: Tenofovir; NS: Non-significant; HCC: Hepatocellular carcinoma.

**Table 2 Risk scoring system for hepatocellular carcinoma in chronic hepatitis B**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **CU-HCC score[76]** |  | **GAG-HCC score[75]** |  | **REACH-B score[77]** |  |
| **Variable** | **Points** | **Variable** | **Points** | **Variable** | **Points** |
| **Age** |  | **Age** |  | **Age** |  |
| > 50 yr | 3 | Per year | 1 | Per 5 years over 30 | 1 |
| **Albumin** |  | **Gender** |  | **Gender** |  |
| < 3.5 g/dL | 20 | Male | 16 | Male | 2 |
| **Bilirubin** |  | **BCP mutations** |  | **ALT (IU/L)** |  |
| > 1.1 mg/dL | 1.5 | present | 19 | 15-44 | 1 |
| **Cirrhosis** |  | **Cirrhosis** |  | ≥ 45 | 2 |
| presence | 15 | presence | 30 | **HBeAg (+)** | 2 |
| **HBV-DNA** |  | **HBV-DNA** |  | **HBV-DNA** |  |
| 4-6 log 10 | 1 | per log 10 | 3 | < 4log10 | 0 |
| > 6 log10 | 4 |  |  | 4 - < 5log10 | 3 |
|  |  |  |  | 5 - < 6log10 | 5 |
|  |  |  |  | ≥ 6log10 | 4 |
|  |  |  |  |  |  |
| **Risk category** |  | **Risk category** |  | **Risk category** |  |
| **Low** | < 5 | **Low** | < 101 | A 17 point risk scale |  |
| **Intermediate** | 5-20 | **High** | ≥ 101 |  |  |
| **High** | > 20 |  |  |  |  |

CU-HCC: Chinese University-Hepatocellular Carcinoma Score; GAG-HCC: Guide with Age, Gender, HBV-DNA, Core Promoter Mutations and Cirrhosis; REACH-B: Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B; BCP: Basic core promoter.